Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
View/ Open
Date
2020-12-01ICR Author
Author
Pettitt, AR
Jackson, R
Cicconi, S
Polydoros, F
Yap, C
Dodd, J
Bickerstaff, M
Stackpoole, M
Khan, UT
Carruthers, S
Oates, M
Lin, K
Coupland, SE
Menon, G
Kalakonda, N
McCarthy, H
Bloor, A
Schuh, A
Duncombe, A
Dearden, C
Fegan, C
Kennedy, B
Walewska, R
Marshall, S
Fox, CP
Hillmen, P
Type
Journal Article
Metadata
Show full item recordCollections
Research team
Clinical Trials & Statistics Unit
Language
eng
Date accepted
2020-02-07
License start date
2020-02-13
Citation
Haematologica, 2020
Publisher
FERRATA STORTI FOUNDATION